Want to see IN:ENTERO full AI Analyst Report?
Top Page
Entero Healthcare Solutions Limited
(ENTERO)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹1,919.00
▲(55.91% Upside)
Action:Reiterated
Date:08/25/26
The score is driven primarily by improving profitability and rapid revenue growth, but weighed down by weak cash conversion/near-zero free cash flow and thin, compressing margins. Technically, the trend is strong with positive momentum, though overbought readings add near-term risk. A high P/E with no dividend yield provided further limits the score.
Positive Factors
Revenue Growth
Rapid multi-year revenue expansion indicates that Entero is scaling its pharmaceutical distribution network and increasing transaction volumes. Continued growth broadens operating reach, supports greater customer and supplier relevance, and provides a durable foundation for improving earnings over the next several quarters.
Negative Factors
Weak Cash Conversion
Near break-even free cash flow despite positive earnings indicates that reported profits are not yet converting efficiently into deployable cash. Working-capital intensity or reinvestment needs may continue to restrict financial flexibility, limiting funds available for debt reduction, expansion, or shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Rapid multi-year revenue expansion indicates that Entero is scaling its pharmaceutical distribution network and increasing transaction volumes. Continued growth broadens operating reach, supports greater customer and supplier relevance, and provides a durable foundation for improving earnings over the next several quarters.
Read all positive factors
Entero Healthcare Solutions Limited (ENTERO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹79.18B
Dividend YieldN/A
Average Volume (3M)60.32K
Price to Earnings (P/E)63.0
Beta (1Y)0.61
Revenue Growth31.94%
EPS Growth22.27%
CountryIN
Employees4,671
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)26.44
Shares Outstanding43,523,070
10 Day Avg. Volume22,857
30 Day Avg. Volume60,317
Financial Highlights & Ratios
PEG Ratio2.22
Price to Book (P/B)3.22
Price to Sales (P/S)0.82
P/FCF Ratio3.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,800.00Price Target Upside46.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)39.95
Revenue Forecast (FY)₹82.40B
Entero Healthcare Solutions Limited Business Overview & Revenue Model
Company Description
Established in 2018 and headquartered in Mumbai, India, Entero Healthcare Solutions Limited functions as a key distributor within the Indian healthcare sector. The company specializes in supplying a diverse range of medical and health-related prod...
How the Company Makes Money
Entero Healthcare Solutions Limited primarily makes money by distributing pharmaceutical and healthcare products: it purchases products from manufacturers and sells them to pharmacies, hospitals, and other healthcare customers, earning a gross mar...
Entero Healthcare Solutions Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
67
Positive
Cash Flow
34
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.91B | 50.96B | 39.22B | 33.00B | 25.15B |
| Gross Profit | 3.92B | 2.57B | 3.48B | 1.10B | 2.03B |
| EBITDA | 2.66B | 2.11B | 1.26B | 694.76M | 260.38M |
| Net Income | 1.15B | 948.20M | 391.09M | -115.57M | -299.20M |
Balance Sheet | |||||
| Total Assets | 36.00B | 27.03B | 23.45B | 14.04B | 11.26B |
| Cash, Cash Equivalents and Short-Term Investments | 2.92B | 3.18B | 7.88B | 1.07B | 1.05B |
| Total Debt | 6.77B | 4.05B | 3.38B | 4.38B | 3.55B |
| Total Liabilities | 18.48B | 9.32B | 7.04B | 7.76B | 5.63B |
| Stockholders Equity | 16.89B | 17.24B | 16.38B | 6.23B | 5.61B |
Cash Flow | |||||
| Free Cash Flow | 17.80M | -916.38M | -420.28M | -508.34M | -451.32M |
| Operating Cash Flow | 693.22M | -803.24M | -366.12M | -453.15M | -352.66M |
| Investing Cash Flow | -3.17B | 1.82B | -7.05B | -485.95M | -1.62B |
| Financing Cash Flow | 1.64B | -320.99M | 8.63B | 727.64M | 2.11B |
Entero Healthcare Solutions Limited Technical Analysis
Positive
1230.80
Price Trends
1426.10
Positive
1307.91
Positive
1206.09
Positive
Market Momentum
129.65
Positive
70.43
Negative
34.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ENTERO, the sentiment is Positive. The current price of 1230.8 is below the 20-day moving average (MA) of 1683.79, below the 50-day MA of 1426.10, and above the 200-day MA of 1206.09, indicating a bullish trend. The MACD of 129.65 indicates Positive momentum. The RSI at 70.43 is Negative, neither overbought nor oversold. The STOCH value of 34.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ENTERO.
Entero Healthcare Solutions Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹44.57B | 37.30 | ― | 0.89% | 11.78% | -34.54% | |
72 Outperform | ₹54.52B | 45.14 | ― | 0.13% | 14.96% | 20.76% | |
72 Outperform | ₹76.78B | 56.41 | ― | 0.21% | 20.59% | 27.16% | |
61 Neutral | ₹79.18B | 62.99 | ― | ― | 31.94% | 22.27% | |
61 Neutral | ₹50.91B | 586.58 | ― | 16.67% | 10.83% | -89.82% | |
57 Neutral | ₹37.84B | 12.47 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:ENTERO
Entero Healthcare Solutions Limited
1,819.35
653.60
56.07%
IN:ARTEMISMED
Artemis Medicare Services Ltd.
344.40
103.31
42.85%
IN:BLISSGVS
Bliss Gvs Pharma Limited
722.45
571.42
378.36%
IN:ORCHPHARMA
Orchid Pharma Limited
1,003.85
294.30
41.48%
IN:RPGLIFE
RPG Life Sciences Limited
2,694.75
360.96
15.47%
IN:UNICHEMLAB
Unichem Laboratories Limited
537.45
34.20
6.80%
Entero Healthcare Solutions Limited Corporate Events
Entero Healthcare Subsidiary Pays GST Penalty Under Protest, Plans Refund Claim
Sep 12, 2026
Entero Healthcare Solutions has disclosed that its subsidiary, ACE Cardiopathy Solutions, has been hit with a Goods and Services Tax penalty by the Uttar Pradesh GST Authority for non-generation of an e-invoice. The authority levied a monetary pen...
Entero Healthcare posts Q1 FY27 earnings call transcript for investors
Aug 17, 2026
Entero Healthcare Solutions Limited has notified stock exchanges that it has made available the transcript of its Q1 FY27 earnings conference call held on August 10, 2026, which discussed the unaudited financial results for the quarter ended June ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.